Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Spectrum Pharmaceuticals, Inc
EVIVE Biotechnology
Aileron Therapeutics, Inc.
Canadian Cancer Trials Group
Wake Forest University Health Sciences
Jiangsu T-Mab Biopharma Co.,Ltd
Tianjin SinoBiotech Ltd.